Rezafungin

CHEMBL3989945 Phase 4 Onaylandı Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

1226.4 g/mol

LogP

2.9

Phase

4

Rezafungin is a novel long-acting echinocandin antifungal agent that inhibits beta-1,3-D-glucan synthase, an enzyme essential for fungal cell wall biosynthesis, disrupting cell wall integrity and causing osmotic instability and fungal cell death. Its extended half-life allows once-weekly intravenous dosing, distinguishing it from other echinocandins, and it has activity against Candida species including fluconazole-resistant strains and Pneumocystis jirovecii.

Moleküler Ağırlık

1226,4000 g/mol

LogP

2,90

TPSA

366,00 Å²

Lipinski RO5

Başarısız

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D Yapı

SVG PNG

Cite this structure

Embed this structure

SMILES

CCCCCOc1ccc(-c2ccc(-c3ccc(C(=O)N[C@H]4C[C@@H](O)[C@@H](OCC[N+](C)(C)C)NC(=O)[C@@H]5[C@@H](O)[C@@H](C)CN5C(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@H](O)[C@@H](O)c5ccc(O)cc5)NC(=O)[C@@H]5C[C@@H](O)CN5C(=O)[C@H]([C@@H](C)O)NC4=O)cc3)cc2)cc1

InChI

InChI=1S/C63H84N8O17/c1-8-9-10-28-87-45-25-21-40(22-26-45)38-13-11-37(12-14-38)39-15-17-42(18-16-39)56(80)64-46-31-48(76)61(88-29-27-71(5,6)7)68-60(84)52-53(77)34(2)32-70(52)63(86)50(36(4)73)66-59(83)51(55(79)54(78)41-19-23-43(74)24-20-41)67-58(82)47-30-44(75)33-69(47)62(85)49(35(3)72)65-57(46)81/h11-26,34-36,44,46-55,61,72-73,75-79H,8-10,27-33H2,1-7H3,(H5-,64,65,66,67,68,74,80,81,82,83,84)/p+1/t34-,35+,36+,44+,46-,47-,48+,49-,50-,51-,52-,53-,54-,55-,61+/m0/s1

Molecular Formula

C63H85N8O17+

HBD / HBA

13 / 17

Döndürülebilir Bağlar

18

Ağır Atomlar

88

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Sıkça Sorulan Sorular

Rezafungin is a novel long-acting echinocandin antifungal agent that inhibits beta-1,3-D-glucan synthase, an enzyme essential for fungal cell wall biosynthesis, disrupting cell wall integrity and causing osmotic instability and fungal cell death. Its extended half-life allows once-weekly intravenous dosing, distinguishing it from other echinocandins, and it has activity against Candida species including fluconazole-resistant strains and Pneumocystis jirovecii.

Yes, Rezafungin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL3989945. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 78318119. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

Hasta dostu bilgi mi arıyorsunuz?

Rezafungin PillFYI'da

Yapı

Hızlı Veriler

Formül: C63H85N8O17+
Eş Anlamlılar: 1

Dış Bağlantılar

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Tıbbi Sorumluluk Reddi

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.